Exudative AMD subtypes and eligibility for treatment with ranibizumab

S. George, C. Cooke, Usha Chakravarthy

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Purpose To ascertain the proportion of patients with neovascular age-related macular degeneration (AMD) eligible for intravitreal treatment with monoclonal antibodies to vascular endothelial growth factor, on the basis of inclusion criteria used in pivotal clinical trials.
Original languageEnglish
Pages (from-to)1247-1251
Number of pages5
Issue number7
Publication statusPublished - Jul 2010

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Exudative AMD subtypes and eligibility for treatment with ranibizumab'. Together they form a unique fingerprint.

Cite this